Caribou Biosciences Share Price Today
(NASDAQ: CRBU)

Name: Caribou Biosciences Share Price Today (NASDAQ: CRBU) - Caribou Biosciences Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Caribou Biosciences share price is $1.15 & ₹100.01 as on 6 Mar 2025, 2.30 'hrs' IST

$1.15

▲

0.05

(4.55%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Caribou Biosciences share price in Dollar and Rupees. Guide to invest in Caribou Biosciences stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Caribou Biosciences, along with analyst recommendations, forecasts, and comprehensive financials.

Caribou Biosciences share price movements

Today's Low: $1.08
Today's High: $1.16
$1.15
6.09%
Downside
Day's Volatility :6.9%
Upside
0.86%
52 Weeks Low: $1.01
52 Weeks High: $7.74
$1.15
12.0%
Downside
52 Weeks Volatility :86.93%
Upside
85.14%

Caribou Biosciences (CRBU) Returns

Period	Caribou Biosciences	Sector (Health Care)	Index (Russel 2000)
3 Months	-41.62%	3.7%	0.0%
6 Months	-37.16%	-2.8%	0.0%
1 Year	-84.48%	2.5%	0.0%
3 Years	-87.29%	12.9%	-11.6%

Caribou Biosciences (CRBU) Key Statistics

in dollars & INR

Previous Close	$1.1
Open	$1.12
Today's High	$1.16
Today's Low	$1.08
Market Capitalization	$99.6M
Today's Volume	$1.1M
52 Week High	$7.74
52 Week Low	$1.012
Revenue TTM	$11.5M
EBITDA	$-157.8M
Earnings Per Share (EPS)	$-1.71
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-43.6%

How to invest in Caribou Biosciences Stock (CRBU) from India?

It is very easy for Indian residents to invest directly in Caribou Biosciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Caribou Biosciences stock in both Indian Rupees (INR) and US Dollars (USD). Search for Caribou Biosciences or CRBU on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Caribou Biosciences or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Caribou Biosciences shares which would translate to 0.756 fractional shares of Caribou Biosciences as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Caribou Biosciences, in just a few clicks!

Returns in Caribou Biosciences (CRBU) for Indian investors in Rupees

The Caribou Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Caribou Biosciences investment value today

Current value as on today

₹20,468

Returns

₹79,532

(-79.53%)

Returns from Caribou Biosciences Stock

₹84,480 (-84.48%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Caribou Biosciences (CRBU)

-33%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Caribou Biosciences Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Caribou Biosciences

BlackRock Inc
7.25%
Vanguard Group Inc
5.04%
Partner Fund Management LP
4.28%
Morgan Stanley - Brokerage Accounts
3.04%
JPMorgan Chase & Co
2.76%
Kynam Capital Management, LP
2.66%

Analyst Recommendation on Caribou Biosciences

Buy

86%Buy

13%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Caribou Biosciences(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Caribou Biosciences Stock (CRBU)

What analysts predicted

Upside of 1052.17%

Target:

$13.25

Current:

$1.15

Insights on Caribou Biosciences Stock (Ticker Symbol: CRBU)

Price Movement
In the last 3 months, CRBU stock has moved down by -46.0%
Decreasing Revenue
Revenue is down for the last 2 quarters, 3.46M → 2.02M (in $), with an average decrease of 41.6% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -41.23M → -34.68M (in $), with an average increase of 9.0% per quarter
CRBU vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 151.0%
CRBU vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 138.7%
Price to Sales
ForCRBU every $1 of sales, investors are willing to pay $9.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

CRBU Caribou Biosciences Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$5.8M	-
Net Income	$-23.4M	-
Net Profit Margin	-404.82%	-

	FY20	Y/Y Change
Revenue	$12.4M	↑ 113.56%
Net Income	$-34.3M	↑ 46.42%
Net Profit Margin	-277.55%	↑ 127.27%

	FY21	Y/Y Change
Revenue	$9.6M	↓ 22.35%
Net Income	$-66.9M	↑ 95.07%
Net Profit Margin	-697.26%	↓ 419.71%

	FY22	Y/Y Change
Revenue	$13.9M	↑ 44.31%
Net Income	$-99.4M	↑ 48.56%
Net Profit Margin	-717.79%	↓ 20.53%

	FY23	Y/Y Change
Revenue	$34.5M	↑ 148.91%
Net Income	$-102.1M	↑ 2.66%
Net Profit Margin	-296.05%	↑ 421.74%

	Q2 FY23	Q/Q Change
Revenue	$3.8M	↑ 7.22%
Net Income	$-29.5M	↑ 18.14%
Net Profit Margin	-786.13%	↓ 72.62%

	Q3 FY23	Q/Q Change
Revenue	$23.7M	↑ 530.15%
Net Income	$-10.0M	↓ 66.12%
Net Profit Margin	-42.27%	↑ 743.86%

	Q4 FY23	Q/Q Change
Revenue	$3.6M	↓ 84.96%
Net Income	$-34.5M	↑ 244.98%
Net Profit Margin	-969.79%	↓ 927.52%

	Q1 FY24	Q/Q Change
Revenue	$2.4M	↓ 31.73%
Net Income	$-41.2M	↑ 19.5%
Net Profit Margin	-1.7K%	↓ 727.78%

	Q2 FY24	Q/Q Change
Revenue	$3.5M	↑ 42.61%
Net Income	$-37.7M	↓ 8.58%
Net Profit Margin	-1.1K%	↑ 609.32%

	Q3 FY24	Q/Q Change
Revenue	$2.0M	↓ 41.57%
Net Income	$-34.7M	↓ 7.99%
Net Profit Margin	-1.7K%	↓ 625.39%

	FY19	Y/Y Change
Profit	$-17.8M	-

	FY20	Y/Y Change
Profit	$-22.1M	↑ 23.63%

	FY21	Y/Y Change
Profit	$8.6M	↓ 139.04%

	FY22	Y/Y Change
Profit	$10.2M	↑ 18.53%

	FY23	Y/Y Change
Profit	$-77.6M	↓ 860.02%

	Q2 FY23	Q/Q Change
Profit	$2.6M	↑ 9.63%

	Q3 FY23	Q/Q Change
Profit	$21.6M	↑ 719.93%

	Q4 FY23	Q/Q Change
Profit	$1.6M	↓ 92.65%

	Q1 FY24	Q/Q Change
Profit	$1.7M	↑ 8.52%

	Q2 FY24	Q/Q Change
Profit	$2.6M	↑ 51.72%

	Q3 FY24	Q/Q Change
Profit	$2.0M	↓ 22.39%

	FY19	Y/Y Change
Operating Cash Flow	$-32.0M	-
Investing Cash Flow	$27.2M	-
Financing Cash Flow	$172.0K	-

	FY20	Y/Y Change
Operating Cash Flow	$-33.2M	↑ 3.78%
Investing Cash Flow	$6.4M	↓ 76.63%
Financing Cash Flow	$1.7M	↑ 908.72%

	FY21	Y/Y Change
Operating Cash Flow	$-32.5M	↓ 2.1%
Investing Cash Flow	$-176.4M	↓ 2872.23%
Financing Cash Flow	$433.4M	↑ 24881.5%

	FY22	Y/Y Change
Operating Cash Flow	$-91.0M	↑ 179.73%
Investing Cash Flow	$-93.2M	↓ 47.14%
Financing Cash Flow	$2.1M	↓ 99.51%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-15.2M	↓ 45.65%
Investing Cash Flow	$11.1M	↓ 46.56%
Financing Cash Flow	$17.6M	↑ 970.1%

Caribou Biosciences Technicals Summary

Sell

Neutral

Buy

Caribou Biosciences is currently in a neutral trading position according to technical analysis indicators.

Caribou Biosciences (CRBU) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Caribou Biosciences	-17.86%	-37.16%	-84.48%	-87.29%	-92.95%
Regeneron Pharmaceuticals, Inc.	-1.42%	-40.28%	-29.31%	11.08%	44.83%
Beone Medicines Ltd	17.63%	36.87%	64.37%	45.89%	71.3%
Vertex Pharmaceuticals Incorporated	1.94%	4.92%	19.37%	108.73%	123.83%
Alnylam Pharmaceuticals, Inc.	-8.03%	-0.89%	66.53%	52.9%	126.66%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Caribou Biosciences	NA	NA	NA	-1.7	-0.44	-0.25	NA	3.11
Regeneron Pharmaceuticals, Inc.	17.86	17.86	1.01	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.34	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Caribou Biosciences	Buy	$99.6M	-92.95%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$73.8B	44.83%	17.86	31.07%
Beone Medicines Ltd	NA	$29.1B	71.3%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.9B	123.83%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	126.66%	NA	-12.37%

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Organization	Caribou Biosciences
Employees	158
CEO	Dr. Rachel E. Haurwitz Ph.D.
Industry	Services

Management People of Caribou Biosciences

Name	Title
Dr. Rachel E. Haurwitz Ph.D.	Co-Founder, CEO, President & Director
Dr. Steven B. Kanner Ph.D.	Chief Scientific Officer
Ms. Barbara G. McClung Esq., J.D.	Chief Legal Officer & Corporate Secretary
Mr. Sriram Ryali M.B.A.	Chief Financial Officer
Mr. Daniel Poon	Vice President of Operations & Information Technology
Mr. Ryan Fischesser	Interim Principal Accounting Officer & Controller
Mr. Timothy P. Kelly M.B.A.	Chief Technology Officer
Ms. Amy Figueroa C.F.A.	Vice President of Investor Relations & Corporate Communications
Ms. Reigin Zawadzki	Chief People Officer
Ms. Ruhi A. Khan M.B.A.	Chief Business Officer

Important FAQs about investing in CRBU Stock from India :

What is Caribou Biosciences share price today?

Caribou Biosciences share price today stands at $1.15, Open: $1.12 ; Previous Close: $1.10 ; High: $1.16 ; Low: $1.08 ; 52 Week High: $7.74 ; 52 Week Low: $1.01.

The stock opens at $1.12, after a previous close of $1.10. The stock reached a daily high of $1.16 and a low of $1.08, with a 52-week high of $7.74 and a 52-week low of $1.01.

Can Indians buy Caribou Biosciences shares?

Yes, Indians can invest in the Caribou Biosciences (CRBU) from India.

With INDmoney, you can buy Caribou Biosciences at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Caribou Biosciences at zero transaction cost.

How can I buy Caribou Biosciences shares from India?

It is very easy to buy Caribou Biosciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Caribou Biosciences (CRBU) be purchased?

Yes, you can buy fractional shares of Caribou Biosciences with INDmoney app.

What are the documents required to start investing in Caribou Biosciences stocks?

To start investing in Caribou Biosciences, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.